Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chison Medical Technologies Co., Ltd. (688358.SS)
Wuxi, CN
Chison Medical Technologies Co., Ltd. is primarily engaged in the manufacturing and worldwide distribution of sophisticated medical ultrasound imaging equipment. Their comprehensive product portfolio extends beyond core ultrasound diagnostic systems to include a variety of health-related equipment, advanced instrumentation, electronic components, diverse electronic products and devices, as well as supporting items like trolleys and general accessories. Key offerings within their ultrasound range feature both advanced Color Doppler units and reliable black-and-white (B/W) systems.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.29% | -2.60% | +4.94% | -4.19% | +4.11% | +9.34% | +11.60% | -38.68% | -9.93% | -10.64% | -10.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-7.0% Q1'26: -0.3% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-17.5% Q1'26: +10.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+19.0% Q1'26: -17.2% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+29.6% ★ Q1'26: +39.4% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+36.7% ★ Q1'26: +44.0% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.6% Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.01× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
333.09M
est: 357.17M (-6.7%)
|
397.81M
est: 571.22M (-30.4%)
|
380.84M
est: 695.13M (-45.2%)
|
483.84M
est: 604.00M (-19.9%)
|
468.70M
est: 558.00M (-16.0%)
|
435.81M
est: 502.00M (-13.2%)
|
575.00M
575.00M – 575.00M
+14.5% YoY
|
659.00M
659.00M – 659.00M
+14.6% YoY
|
| EBITDA |
119.70M
est: 122.60M (-2.4%)
|
133.83M
est: 196.08M (-31.7%)
|
127.20M
est: 238.61M (-46.7%)
|
174.60M
est: 207.33M (-15.8%)
|
168.84M
est: 191.26M (-11.7%)
|
140.45M
est: 172.07M (-18.4%)
|
197.09M
197.09M – 197.09M
+14.5% YoY
|
225.88M
225.88M – 225.88M
+14.6% YoY
|
| EBIT |
111.51M
est: 112.15M (-0.6%)
|
124.54M
est: 179.36M (-30.6%)
|
115.13M
est: 218.27M (-47.3%)
|
162.94M
est: 189.66M (-14.1%)
|
157.58M
est: 176.86M (-10.9%)
|
129.19M
est: 159.11M (-18.8%)
|
182.25M
182.25M – 182.25M
+14.5% YoY
|
208.88M
208.88M – 208.88M
+14.6% YoY
|
| Net Income |
99.64M
est: 114.70M (-13.1%)
|
112.47M
est: 176.83M (-36.4%)
|
105.84M
est: 147.20M (-28.1%)
|
146.48M
est: 176.19M (-16.9%)
|
140.51M
est: 191.77M (-26.7%)
|
116.63M
est: 154.76M (-24.6%)
|
176.07M
176.07M – 176.07M
+13.8% YoY
|
201.86M
201.86M – 201.86M
+14.6% YoY
|
| SGA |
56.91M
est: 46.86M (+21.4%)
|
76.15M
est: 74.95M (+1.6%)
|
81.84M
est: 91.21M (-10.3%)
|
84.26M
est: 79.25M (+6.3%)
|
92.63M
est: 93.86M (-1.3%)
|
27.42M
est: 84.44M (-67.5%)
|
96.72M
96.72M – 96.72M
+14.5% YoY
|
110.84M
110.84M – 110.84M
+14.6% YoY
|
| EPS |
0.89
est: 1.03 (-13.5%)
|
1.00
est: 1.59 (-36.9%)
|
0.94
est: 1.32 (-28.8%)
|
1.33
est: 1.58 (-15.8%)
|
1.26
est: 1.71 (-26.3%)
|
1.04
est: 1.38 (-24.6%)
|
1.57
1.57 – 1.57
+13.8% YoY
|
1.80
1.80 – 1.80
+14.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Zhou | Deputy GM, Secretary, Chief Financial Officer, Accounting Supervisor & Director | — | male |
| Ruoli Mo | GM & Chairman | — | female |
| Wang Hong | Chief Technology Officer | — | male |
| Xiaoming Zhu | Innovation Center Director | — | male |
| Zhang Yong | Supervisor & Director of R & D Center High-End Color Doppler Ultrasound | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688358.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
